StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Fidelity Disruptive Investing - Still Accumulating

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Oct 19, 2021 1:53pm

120 Views

Post# 34023486

RE:Fidelity Disruptive Investing - Still Accumulating

Thanks for that

Photoman77 wrote: Been told Fidelity has taken a keen interest in StageZero through their new Disruption Fund.

Good luck driving the price down bashers lol!

Billions in funding to back these boys up.

Accumulation is their game to fill their quotas inside these funds, then it's off to the races.

Hint: These guys don't lose so brace yourselves if you don't think we already achieved bottom. They will back their trucks up in support of the price action.

https://www.fidelity.ca/fidca/en/products/disruption?utm_source=td&utm_medium=display&utm_campaign=inv-prod-PIDIY%20Disruption%20Funds-280921&utm_content=en-ba-dcpm-300x250-Investing_in-inv